Evofem Biosciences, Inc. · Drugmakers

EVFM

Elevated riskNext report: Due any day

View price ↗

The short version

A profitable company with shrinking sales.

Going well

Profitable

Watch out for

Sales down 45% in the latest quarter vs a year ago
Owes more than it owns (negative equity)
Bills due within a year exceed short-term assets

Money moves

No insider buying or selling in the last 30 days

Facts from SEC filings, not a recommendation.

The business over time

Last 12 quarters, from SEC filings

Sales, Jun '26

$2.6M-45% vs a year earlier

Sep '23Tap a barJun '26

Last 12 months: $18.0M, up 4.5% from the 12 months before.

Price

Price chart by TradingView.

Business quality

The checklist Warren Buffett-style investors use. Annual numbers for 2025.

0/4Weak

MissDebt under half of equityNot relying on borrowed money.Owes more than it owns
MissNet margin 10%+Keeps at least 10 cents of profit from each dollar of sales.1.9%
MissProfitable every yearSteady profits, not one good year.2 of 10 years
MissFree cash flow positiveBrings in more cash than it spends to run and grow.-$2.0M

Revenue: $20.2M; +4.2% vs prior year
5-year growth: +114.4%/yr; revenue, per year
Current ratio: 0.18x; short-term assets / bills due
Free cash flow: -$2.0M; -9.9% of revenue

From annual reports filed with the SEC. Not in this company's SEC data, so not scored: return on equity 15%+, share count not growing, gross margin 40%+. A checklist is a starting point for research, not a verdict.

Latest quarter

Quarter ended Jun 30, 2026

Reported May 18

Revenue: $2.6M; -45.4% YoY
EPS: -$0.08; vs -$0.01
Op. margin: -94.5%; -68.6 pts
Gross margin: 80.6%; -3.8 pts
Free cash flow: -$3.1M
Share count: +14.0%; vs a year ago

Insider rating

Last 90 days

No open-market insider buys or sells in the last 90 days.

Weekly insider trend

No trades to chart yet.

Filing buzz

Last 7 days vs normal

0/ 100

This week: 0
Normal week: 0.3
vs normal: 0.0x

SEC filings of any kind. 50 means a normal week.

Safety check

From SEC filings

Share count growthYearly rate, last 3 years

+218.9%

Cash runwayAt last year's cash burn

2 months

Debt to equityLatest balance sheet: debt compared with what owners have

Owes more than it owns

Shares outstandingLatest reported

133M

Why elevated risk

Share count growing 218.9% a year (dilution)
Owes more than it owns (negative equity)
Bills due within a year exceed short-term assets

Earnings reports

Last 12

Next reportDue any dayEstimated from the same quarter last year

Results filedMay 18
Results filedMar 11
Results filedNov 13, 2025
Results filedAug 14, 2025
Results filedMay 15, 2025

Flags and big holders

Offerings 6 months, flags 12 months, holders 90 days

New 5%+ holder (active)Aug 4 · View filing ↗Activist

Insider trades

Open-market buys and sells, last 90 days

No open-market buys or sells in 90 days. Grants and option exercises are left out.

"Owns after" is the insider's holding right after the trade. Pre-planned (10b5-1) sales are set up months ahead, a weaker signal.

Latest filings

Straight from SEC EDGAR

Major agreementOct 15 · Form 8-K ↗Major agreementSep 23 · Form 8-K ↗Quarterly reportAug 14 · Form 10-Q ↗New 5%+ holder (active)Aug 4 · Form SCHEDULE 13D ↗Investor disclosureJul 20 · Form 8-K ↗Major agreementJul 14 · Form 8-K ↗Earnings resultsMay 18 · Form 8-K ↗Quarterly reportMay 15 · Form 10-Q ↗Major agreementApr 30 · Form 8-K ↗Major agreementApr 16 · Form 8-K ↗Current reportMar 19 · Form 8-K ↗Annual reportMar 11 · Form 10-K ↗Earnings resultsMar 11 · Form 8-K ↗Investor disclosureJan 12 · Form 8-K ↗Charter or share changeNov 26, 2025 · Form 8-K ↗

Source: SEC EDGAR filings. For informational purposes. Not investment advice.

Report a problem with this page